Seres Therapeutics has secured up to $3.6 million in additional non-dilutive funding from CARB-X to develop and manufacture an...

Fulcrum Therapeutics reported new Phase 1b data for its oral EED inhibitor, pociredir, in sickle cell disease, showing dose-dependent,...

ADMA Biologics will report third-quarter 2025 results on November 5, alongside a call to discuss performance across its plasma-derived...

OKYO Pharma will use next week’s BIO-Europe meeting in Vienna to spotlight urcosimod, its lipid-anchored chemerin receptor agonist, following...

Genfit will use AASLD The Liver Meeting 2025 to showcase breadth across its hepatology portfolio, led by new preclinical...

Tarsus Pharmaceuticals will host a live webcast on November 4 to report third-quarter 2025 results and deliver a corporate...

The FDA’s Office of Therapeutic Products (OTP) within the Center for Biologics Evaluation and Research (CBER) hosted its Virtual...

Journey Medical’s FDA-approved Emrosi (DFD-29, 40 mg minocycline hydrochloride modified-release) is now available in the United States for adults...

Arcutis Biotherapeutics reported new Phase 3 and long-term extension data showing its topical PDE4 inhibitor, Zoryve (roflumilast) cream 0.15%...

SciSparc has closed a transaction to take a controlling stake in Neurothera Labs Inc., a TSX Venture–listed vehicle that...